Chris Ryan

Los Angeles

Editorial Director at The Ringer

Editorial Director, @ringer; co-host @TheWatchPod (Subscribe: https://t.co/gVFoPdvd5R), @TheRewatchables, Music Exists, @RingerNBA

Articles

What's Up, Doctopher?

1 week ago | chrisryan.substack.com | Chris Ryan

“What’s Up, Doctopher?” is a free occasional newsletter. To gain access to bonus content including BROMAs, TOMAs, travel updates, AMAs, What Makes this Book Great?, the DJCPR series, and a monthly open thread where you can interact with the Tangentially Speaking community, please consider becoming a paid subscriber for $5/month or $50/year — less than a buck a week! (This month’s discussion is a great one: What have you been wrong about recently?) If you’ve already subscribed, much obliged.
Tangentially Speaking with Chris Ryan

1 month ago | chrisryan.substack.com | Chris Ryan

This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts
What's Up, Doctopher?

2 months ago | chrisryan.substack.com | Chris Ryan

“What’s Up, Doctopher?” is a free occasional newsletter.
Tangentially Speaking with Chris Ryan

2 months ago | chrisryan.substack.com | Chris Ryan

This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts
Tangentially Speaking with Chris Ryan

Feb 11, 2025 | chrisryan.substack.com | Chris Ryan

This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts
639 - Vincenzo Barney (Cormac McCarthy and Sudden Fame)

Feb 11, 2025 | chrisryan.substack.com | Chris Ryan

This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts
What's Up, Doctopher?

Feb 8, 2025 | chrisryan.substack.com | Chris Ryan

“What’s Up, Doctopher?” is a free occasional newsletter. To gain access to bonus content including BROMAs, TOMAs, travel updates, AMAs, What Makes this Book Great?, the DJCPR series, and a monthly open thread where you can interact with the Tangentially Speaking community, please consider becoming a paid subscriber for $5/month or $50/year (which is less than a buck a week!). If you’ve already subscribed, much obliged.
Satri-Cel Improves PFS in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer

Jan 3, 2025 | onclive.com | Chris Ryan

Treatment with the Claudin18.2 (CLDN18.2)–directed autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel; CT041) led to a statistically significant improvement in progression-free survival (PFS) compared with physician’s choice of therapy in patients with CLDN18.2-positive advanced gastric/gastroesophageal junction (GEJ) cancer that had progressed following at least 2 prior lines of therapy, according to topline data from the phase 2 CT041-ST-01 trial (NCT04581473).1 Findings...
FDA Approval Sought for Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

Jan 2, 2025 | onclive.com | Chris Ryan

The FDA has received a new drug application (NDA) seeking the accelerated approval of dordaviprone (ONC201) for the treatment for patients with recurrent H3K27M-mutant diffuse glioma.1Chimerix, the developer of dordaviprone, has requested priority review of the NDA by the regulatory agency, which would lead to a potential Prescription Drug User Fee Act target action date in the third quarter of 2025.
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

Dec 23, 2024 | onclive.com | Chris Ryan

The FDA has granted priority review to the new drug application (NDA) seeking the approval of taletrectinib for the treatment of patients with ROS1-positive advanced non–small cell lung cancer.1The NDA is supported by data from a pooled analysis of the phase 2 TRUST-1 (NCT04395677) and TRUST-II (NCT04919811) trials.